Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Material Litigation
confidence 92%
filed 2026-06-22
The filing discloses a threatened shareholder derivative lawsuit in District Court Washoe County, Nevada against current and former directors and officers alleging breach of fiduciary duties and misconduct related to a $3.2 million digital currency loss. Although no complaint has yet been filed, the company received follow-up correspondence in June 2026 from the shareholder's law firm indicating intent to file and attaching a draft complaint seeking monetary and equitable relief. This constitutes material litigation disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-22
Item 8.01
SkinHealth Systems disclosed settlement of a securities class action (Alghazwi v. The Beauty Health Company, Case No. 2:23-cv-09733-SPG-MAA) with a total cash settlement of $18 million, of which the Company will pay $3 million from its own funds. This is a material litigation settlement that would affect a reasonable investor's assessment of the registrant's financial condition and contingent liabilities, disclosed under Item 8.01 (Other Events) as required for material litigation matters.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-06-18
Item 7.01
Two major borrowers filed Chapter 11 bankruptcy, creating $22.0 million in loan exposure (part of a $29.0 million credit facility) for Wayne Bank, the Company's subsidiary. While technically a bankruptcy filing by the borrowers rather than the registrant, this represents a material credit event and potential loss that would significantly affect investor assessment of asset quality and earnings. The Company explicitly states it is "analyzing the potential loss exposure" and will provide further information in its earnings release, signaling materiality.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-18
Item 1.01
The filing discloses a material settlement agreement resolving antitrust class action litigation (In re: PVC Pipe Antitrust Litigation) for $30 million. Although Item 1.01 is cited, the substance is a material litigation settlement that materially affects the company's financial position and reduces significant legal exposure and uncertainty. The $30 million settlement payment and resolution of End-User class claims constitute a material event requiring disclosure under 8-K Item 8.01 (Other Events) or as a material settlement, which falls under material_litigation in this taxonomy.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-18
Item 8.01
Regenerex Pharma commenced litigation against Optimize Health Partners, LLC (owned by the Company's former CFO Kenneth W. Perry) seeking recovery of approximately $37,285 in overbilled amounts plus additional damages, restitution, and injunctive relief. The complaint alleges material breaches of a software license agreement including improper invoice inflation, unauthorized markups, failure to deposit escrow materials, and failure to maintain required insurance—all involving mission-critical healthcare software infrastructure. This is a material litigation disclosure under Item 8.01 that would affect a reasonable investor's assessment of the registrant's financial exposure and operational risks.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses preliminary court approval of a settlement in shareholder derivative litigation (Yingling v. Cannito, et al.) involving breach of fiduciary duty and securities law violations against individual defendants. The settlement requires Redwire to adopt comprehensive corporate governance reforms and pay attorneys' fees funded by insurance. This is a material litigation settlement that affects the company's governance structure and obligations, with a final approval hearing scheduled for July 30, 2026.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 25%
filed 2026-06-17
Item 7.01
A material tenant insolvency affecting 16 properties and $15.2 million in annualized rent, with estimated rent loss of $8–12 million impacting full-year AFFO guidance. While the event does not fit cleanly into traditional litigation categories, it represents a material adverse event to the registrant's cash flows and financial condition.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-06-17
The 6-K discloses settlement of putative class action lawsuits filed against the Company and certain directors in federal and state courts. The Federal Court approved a $7 million settlement agreement on June 1, 2026, resolving the Eastern District of New York action (Case No. 1:22-cv-02604), and a separate state court action was voluntarily dismissed. The disclosure explicitly states "all of the putative class actions filed against the Company in federal and state courts in the U.S. have been resolved," indicating material litigation settlement.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-06-17
EX-99.1
Franco-Nevada discloses a material legal dispute arising from a Burkina Faso court decision purporting to nullify a stream agreement related to the Karma Mine. The company states it believes the judgment is invalid and is pursuing legal remedies in Ontario and elsewhere against Riverstone Karma SA and affiliates to protect its legal rights. This is a material litigation/dispute disclosure that would affect a reasonable investor's assessment of the company's cash-flow-producing assets and portfolio value.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-17
Item 8.01
The filing discloses a material litigation development: a Supreme Court ruling on June 13, 2026 that granted in part and denied in part Fleming Intermediate Holdings LLC's motion to dismiss James River's amended complaint seeking damages for breach of contract related to a failed transaction closure. The Court allowed the Company's claims for direct damages to proceed, which represents a significant litigation milestone affecting the registrant's potential recovery and financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-16
Item 8.01
The filing discloses three lawsuits challenging the proposed merger transaction filed in New York Supreme Court (Phillips v. Green Dot, Richardson v. Green Dot, and Zaccagnino v. Brewster), plus demand letters from purported stockholders alleging disclosure deficiencies in the proxy statement/prospectus. Although the company denies merit and made supplemental disclosures to mitigate litigation risk, the existence of multiple shareholder class-action-style challenges to a material M&A transaction constitutes material litigation that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-06-16
Item 8.01
Forward Industries received a letter from Brera Holdings' counsel alleging violations of federal securities laws under Section 13(d)(3) of the Securities Exchange Act regarding undisclosed group formation and potential Rule 13d-5 violations. While Forward Industries disputes the contentions as meritless, the allegation of securities law violations by a third party constitutes a material regulatory/legal matter requiring disclosure. The forward-looking statements section further emphasizes legal and regulatory uncertainty as a material risk factor.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-16
Item 8.01
The filing discloses a settlement agreement in the litigation Augenbaum v. Anson Investments Master Fund LP et al. in which the Company received aggregate settlement payments of $50,000,000 (minus plaintiff's counsel fees and expenses), with court approval on June 11, 2026. This represents a material litigation settlement that would affect a reasonable investor's assessment of the registrant's financial position and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-12
Item 8.01
This disclosure reports a jury verdict in a wrongful termination and whistleblower protection lawsuit against Ameris Bank, with a total judgment of approximately $79.4 million ($16.525 million in economic/non-economic damages plus $62.9 million in punitive damages). The Company explicitly states the verdict "could have a material adverse effect on the Company's results of operations, financial condition and liquidity," and is evaluating whether an accrual is required for financial reporting purposes, indicating materiality to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-06-11
Item 5.02
The filing discloses commencement of legal proceedings by Regenerex Pharma against its former Chief Financial Officer, Kenneth W. Perry, seeking recovery of funds and other amounts allegedly owed, plus injunctive relief and damages. While filed under Item 5.02 (executive departures/appointments), the substantive disclosure centers on material litigation initiated by the company against a former executive officer, making this a material litigation event. The involvement of a CFO and allegations of misconduct during tenure would affect a reasonable investor's assessment of the company's governance and financial controls.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-11
Item 8.01
The PIPC announced approximately $410 million in aggregate administrative fines against Coupang Corp. for data protection violations, including a previously disclosed November 2025 data incident and separate violations related to third-party advertising data collection. The company disclosed it will recognize these fines in Q2 2026 operating results and pursue judicial review in Seoul Administrative Court. This represents a material regulatory enforcement action with substantial financial consequences that would affect a reasonable investor's assessment of the company's financial condition and regulatory exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-10
Item 8.01
The Company disclosed two material litigation matters: a putative securities class action (Barnes et al. v. Perpetua Resources Corp.) where the court granted a motion to dismiss the amended complaint without prejudice, allowing a second amended complaint by July 3, 2026; and an environmental lawsuit relating to the Stibnite Gold Project where the court denied plaintiffs' preliminary injunction motion on May 29, 2026, with cross-motions for summary judgment and oral argument scheduled for June 24, 2026.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-10
Item 8.01
Getty Images discloses an adverse court decision in Funicular Funds LP v. Getty Images Holdings, Inc., with the court granting summary judgment to plaintiffs on warrant breach claims and directing entry of judgment for approximately $67.8 million plus pre-judgment interest. This material litigation outcome—a judicial determination of liability and damages—directly affects the company's financial position and has been reserved against on the balance sheet, making it a significant material event requiring disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-09
Silver Bull disclosed the dismissal of its arbitration claim against Mexico by the ICSID tribunal on May 29, 2026, with the company ordered to pay approximately US$998,000 in Mexico's legal costs. The arbitration arose from Mexico's expropriation of Silver Bull's Sierra Mojada property and represents a material adverse outcome affecting the company's strategic position and financial obligations. This is a material litigation/arbitration settlement outcome that would significantly impact investor assessment of the company's asset base and future prospects.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-08
Item 8.01
Katapult settled a putative patent infringement lawsuit filed by Flexshopper alleging infringement of five U.S. patents and seeking injunctive relief and damages. The settlement grants Katapult and its affiliates (including Aaron's and CCFI) a perpetual, royalty-free license to the patents and includes mutual releases and covenants not to sue. This material litigation settlement eliminates significant legal risk and is disclosed under Item 8.01 (Other Events), a standard venue for material litigation outcomes.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-06-08
The filing discloses a favorable appellate court decision in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc., where the U.S. Court of Appeals for the Federal Circuit affirmed that Nexus's generic minocycline product infringed two of CorMedix's patents and rejected the invalidity challenge. This is a material litigation outcome that protects the Company's intellectual property and competitive position, warranting disclosure under Item 7.01 as a material event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-08
Item 8.01
The disclosure reports a final arbitration award (June 2, 2026) involving a reinsurance agreement dispute between Kestrel's subsidiary Maiden Reinsurance and a cedant. The arbitration panel found an intentional and material breach by the cedant, awarded $1.0 million in attorneys' fees to the registrant, and mandated substantial adjustments to billing, reserves, and security—including potential repayment of approximately $10.8 million previously paid. The registrant explicitly states it is "evaluating the effect of the Final Award" with uncertain financial statement impacts, signaling material consequences to the company's financial position and obligations under the reinsurance agreement.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-08
Item 8.01
The disclosure reports settlement of litigation in Augenbaum v. Anson Investments Master Fund LP et al. with aggregate settlement payments of $28,475,000 to the Company. This represents a material litigation settlement that would significantly affect a reasonable investor's assessment of the registrant's financial position and legal exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-05
Item 8.01
This disclosure describes the settlement of a material regulatory investigation by the SEC and DOJ into alleged violations of trade allocation laws by Western Asset, a wholly-owned subsidiary of Franklin Resources. The $100 million civil penalty and Fair Fund payment represent a significant financial obligation and regulatory resolution that would materially affect a reasonable investor's assessment of the company's regulatory compliance and financial position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-05
Item 7.01
iRhythm disclosed a binding settlement agreement resolving a putative class action securities litigation for $45 million. The settlement is material to investors as it eliminates significant litigation risk and financial exposure, with the company expecting insurance to cover a majority of the payment. The disclosure explicitly addresses the resolution of previously-disclosed litigation and its financial impact.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-06-05
Item 8.01
This disclosure describes a stockholder class action lawsuit challenging the validity of the Company's advance notice and stockholder nomination provisions in its By-laws. Although the action was dismissed as moot following the Company's September 2024 By-laws Amendment, the Company agreed to pay $120,000 in attorneys' fees and expenses to resolve the fee application. The settlement and litigation history would affect a reasonable investor's assessment of governance risk and the Company's willingness to modify bylaws in response to legal challenge.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-04
Item 8.01
Cooper Companies disclosed a material litigation settlement related to a December 2023 recall of CooperSurgical's LifeGlobal embryo culture media, accruing $271.6 million in net litigation liabilities (after insurance recoveries) to resolve over 95% of more than 1,500 claimants across 140+ lawsuits and three putative class actions.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-04
Item 1.01
Atkore entered into a $50 million settlement agreement on June 3, 2026 with the End User Plaintiffs in the In re PVC Pipe Antitrust Litigation, resolving claims related to alleged coordinated conduct in the PVC pipe and conduit industry. The settlement is material to investors as it resolves significant antitrust litigation exposure, reduces legal uncertainty, and will be recorded as a non-operating expense in Q2 2026, though the company states it is not expected to materially impact liquidity or leverage metrics.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-03
Item 8.01
This disclosure concerns a material qui tam lawsuit filed by a former employee against Corcept in February 2017 alleging improper sales and promotion practices related to Korlym®, with DOJ investigation (subpoena issued November 2021) and an amended complaint served June 2, 2026. The DOJ's declination to intervene does not eliminate the litigation risk; the Relator proceeds independently. This is a material regulatory/litigation matter affecting the company's legal exposure and product reputation.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-03
Item 8.01
The filing discloses settlement of patent litigation involving SUNOSI® (solriamfetol), a key product for Axsome Therapeutics. Patent litigation settlements can materially affect product exclusivity, market access, and competitive positioning. The press release title explicitly references "Settlement Resolving All SUNOSI® Patent Litigation," indicating comprehensive resolution of patent disputes that would be material to investors assessing the company's intellectual property protection and commercial prospects.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-02
Item 8.01
This disclosure centers on an adverse court decision in patent litigation involving CINVANTI, a key product. The District Court held that Heron's asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid (June 1, 2026 decision), which directly threatens the company's ability to block generic competition from Azurity/Slayback. The litigation spans multiple years and involves substantial patent disputes; the adverse ruling is material to investors assessing Heron's product protection and competitive position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-06-02
Item 8.01
UroGen disclosed settlement and termination of patent litigation with Teva regarding Jelmyto, resolving a dispute over a generic ANDA submission. The settlement grants Teva a non-exclusive license to sell generic Jelmyto beginning September 15, 2030, and terminates all ongoing patent litigation in the U.S. District Court for the District of Delaware. This material litigation settlement directly affects the Company's competitive position and revenue protection for a key product.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-02
The filing discloses a trade libel lawsuit filed by Dragonfly Energy Holdings Corp. against William Errol Prowse IV and Prowse Publications LLC on June 1, 2026, alleging a sustained campaign of false and misleading statements that caused financial and reputational harm to the company's Battle Born Batteries brand. The complaint seeks damages and injunctive relief, making this a material litigation event that would affect a reasonable investor's assessment of the company's reputation, brand value, and potential financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-01
Item 8.01
The disclosure centers on a U.S. District Court's denial of a preliminary injunction motion filed by environmental advocacy groups challenging the USFS's approval of the Company's Stibnite Gold Project under the National Environmental Policy Act. The court's decision is material because it removes a significant legal obstacle to the Company's planned construction activities and allows the project to proceed, directly affecting the registrant's ability to execute its development strategy. The litigation itself—involving federal agencies, environmental groups, and allegations of regulatory violations—is material to investors assessing project risk and timeline.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-01
Item 8.01
The filing discloses a jury verdict and amended final judgment in a supplier dispute with Ardagh Metal Packaging USA Corp., resulting in damages of $175.5 million plus $15.5 million in pre-judgment interest (combined $191.0 million pre-tax total). This material litigation event, involving a substantial financial judgment against the Company, would significantly affect a reasonable investor's assessment of Boston Beer's financial position and liabilities. The Company intends to pursue appellate remedies, indicating ongoing litigation exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-29
Item 8.01
The filing discloses eXp World Holdings' participation in a settlement of putative class action litigation (Tuccori Action) following preliminary court approval on May 26, 2026. The Company entered into an Opt-In Settlement Agreement on April 14, 2026, and the settlement is expected to resolve claims with the same factual predicates as the Batton Action. This is a material litigation settlement that would affect investor assessment of the Company's legal and financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-05-29
Item 1.01
The filing discloses a material dispute between Cardiff Oncology and Nerviano Medical Sciences involving a license agreement termination and competing claims of material breach. Cardiff filed a lawsuit on May 19, 2026 seeking injunctive relief and declaratory judgment, and NMS responded with a termination notice on May 27, 2026 alleging breaches related to patent inventorship and failure to conduct development activities for onvansertib. While Item 1.01 nominally covers "Entry into a Material Definitive Agreement," the substance here is a material litigation and contractual dispute that would significantly affect a reasonable investor's assessment of the company's rights to key intellectual property and product development obligations.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-29
Item 1.01
The filing discloses settlement of putative federal antitrust class action litigation (In re: PVC Pipe Antitrust Litigation) with two of three plaintiff classes, involving aggregate settlement payments of $73.5 million ($39.5 million to Direct Purchasers and $34.0 million to Non-Converter Seller Purchasers). This material litigation settlement would significantly affect a reasonable investor's assessment of the company's financial exposure and legal risk, even though the company does not admit wrongdoing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-29
Item 8.01
CEA Industries filed a complaint in U.S. District Court against 10X Capital LLC seeking to void an Asset Management Agreement as unconscionable and recover all fees paid since inception, or alternatively to invalidate a liquidated damages clause that would accelerate nearly 20 years of future fees. This is material litigation that directly affects the Company's financial obligations and contractual relationships, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-29
Item 8.01
This disclosure reports preliminary court approval of a settlement in a stockholder derivative action (In re Olaplex Holdings, Inc. Stockholder Derivative Litigation, Lead Case No. 2:23-cv-09712-SVW-SK) involving claims similar to those in a 2022 securities class action. The settlement requires governance enhancements and payment of attorneys' fees, making it material to investors' assessment of the company's litigation exposure and governance practices.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-28
Item 8.01
The Company disclosed a pending settlement agreement with the United States Trustee resolving claims brought by the State of New Mexico for $1.0 million, relating to legacy helium and gas assets and environmental obligations. Separate claims against the CEO remain pending.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-05-28
Item 8.01
Virgin Galactic disclosed preliminary court approval of a settlement in consolidated stockholder derivative lawsuits (In re Virgin Galactic Holdings, Inc. Derivative Litigation and St. Jean v. Branson et al.) against the company and named officers, with a final hearing scheduled.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-05-27
Item 8.01
Craft Capital Management LLC filed a FINRA arbitration claim against the Company seeking approximately $1.76 million in success fees and warrant value, plus additional equitable relief and attorneys' fees, arising from an alleged breach of contract related to an $11 million private placement transaction.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-22
Item 8.01
The disclosure reports an adverse court ruling in a Clean Water Act lawsuit brought by Community Environmental Advocates against Rise Grass Valley Inc., a subsidiary of Rise Gold Corp. The U.S. District Court granted Summary Judgment in favor of the plaintiff, finding the company allegedly responsible for unpermitted pollutant discharges (metals including arsenic) into a local creek. This is a material litigation event with significant environmental and regulatory implications for the company's mining operations.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-05-22
Item 8.01
This disclosure describes a putative stockholder class action filed against MasterCraft challenging a stockholders agreement provision and a certificate of amendment filing. Although the claims were mooted through settlement and amendment, the Company agreed to pay $425,000 in attorneys' fees and expenses, and the Court entered an order closing the action on May 19, 2026. This settlement of material litigation is a significant event affecting the registrant's financial position and would be material to a reasonable investor.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-05-20
Item 8.01
The filing discloses three lawsuits challenging the proposed merger between Stellar Bancorp and Prosperity Bancshares, filed in New York Supreme Court in May 2026, plus demand letters from purported shareholders. Although the companies deny merit and made supplemental disclosures to avoid litigation delays, the disclosure of material litigation related to a pending merger transaction is a core 8-K Item 8.01 event that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-05-19
Item 8.01
Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences in U.S. District Court for the Southern District of California seeking injunctive relief and declaratory judgment regarding an alleged material breach of a license agreement for onvansertib. The dispute centers on patent inventorship obligations and continuation patent applications, with Cardiff disputing NMS's breach allegations. This is a material litigation event that would affect investor assessment of the company's ability to maintain its license rights and product development.
View raw filing on EDGAR →